PT - JOURNAL ARTICLE AU - Daniele Melo Sardinha AU - Karla Valéria Batista Lima AU - Ana Lúcia da Silva Ferreira AU - Juliana Conceição Dias Garcez AU - Thalyta Mariany Rêgo Lopes Ueno AU - Yan Corrêa Rodrigues AU - Anderson Lineu Siqueira dos Santos AU - Rosane do Socorro Pompeu Loiola AU - Ricardo José de Paula Souza e Guimarães AU - Luana Nepomuceno Gondim Costa Lima TI - Clinical characteristics of Severe Acute Respiratory Syndrome by COVID-19 in Indigenous of Brazil AID - 10.1101/2020.10.24.20218701 DP - 2020 Jan 01 TA - medRxiv PG - 2020.10.24.20218701 4099 - http://medrxiv.org/content/early/2020/12/19/2020.10.24.20218701.short 4100 - http://medrxiv.org/content/early/2020/12/19/2020.10.24.20218701.full AB - Background The indigenous people of Brazil present several cases and deaths, affecting 158 peoples, with high vulnerability and limited access to health services.Objective Investigate the clinical characteristics of severe acute respiratory syndrome by COVID-19 in indigenous peoples of Brazil.Method The epidemiological, cross-sectional, and analytical study, from the data of the platform opendataSUS referring to the SIVEP-GRIPE in the period of 01/01/2020 until 31/08/2020. Profile variables, signs and symptoms, and risk factors/comorbidities. The data were analyzed by Bioestat 5.3.Results 1,207 cases and 470 deaths. Profile: male gender (59.48%) mean age 53. Signs and symptoms: fever (74.23%), cough (77.71%), sore throat (35.62%), dyspnea (69.34%), respiratory discomfort (62.80%), O2 saturation <95% (56.42%); and associated with mortality: dyspnea (80.0%) and O2 saturation <95% (69.36%). Risk factors and comorbidities (45.89%) were associated with deaths (54.04%). Comorbidities: Chronic Cardiovascular Disease (18.97%) and Diabetes Mellitus (18.97%), and associated with deaths: Chronic Cardiovascular Disease (24.46%). There was significance in the survivors vaccinated for influenza (26.18%).Conclusion The public and health policies of Brazil should be directed to control the dissemination of COVID-19 in this population, that COVID-19 evolves in the same intensity, however, the indigenous have vulnerabilities that can enhance the impact of the pandemic in this population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementConselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPQ) Coordenaccaoo de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:all authors have authorized the publicationAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesdata are available on the opendatasus platform of the Brazilian Ministry of health